Immunotherapy: Open Access
Open Access

Shenzhen International Institute for Biomedical Research, Shenzhen, Guangdong, China

Biography

Dongyao Ni. Chief Operating Officer and Head of Clinical Operation. Dongyao Ni is currently Chief Medical Officer at Immvira.
At Immvira, Dongyao Ni has 6 colleagues including Grace Zhou (CEO), Ralph Weichselbaum. In the Biotechnology industry, Dongyao Ni has 22,193 colleagues in 1,793 companies located in 41 countries. 13,472 executive movements have been recorded in the last 12 months. 

Publications

• Research   
  Enhancement of Oncolytic Activity of oHSV Expressing IL-12 and Anti PD-1 Antibody by Concurrent Administration of Exosomes Carrying CTLA-4 miRNA
  Author(s): Runbin Yan, Xusha Zhou, Xiaoqing Chen, Xianjie Liu, Yuxin Tang, Jie Ma, Lei Wang, Ziwen Liu, Borui Zhan, Hong Chen, Jiamei Wang, Weixuan Zou, Huinan Xu, Ruitao Lu, Dongyao Ni*, Bernard Roizman* and Grace G Zhou*
  
  Systemic administration of checkpoint inhibitors alone and especially concurrent with intratumoral administration of oncolytic herpesviruses (oHSV) has a major impact on cancer therapy marred by rare failures of healthy organs. Furthermore, tumors vary with respect to susceptibility to oncolytic effects of oHSV. Here we report the construction and properties of 3 families of oncolytic herpes simplex viruses expressing no immunomodulatory genes (T1 series), murine IL-12 (T2 series) or murine or human IL-12 and anti PD-1 antibody (T3 series). We report that insertion of the gene encoding PD-1 Ab significantly augmented the oncolytic activity of oHSV bereft of immunostimulatory genes (T1 series) or expressing IL-12 alone (T2 series). The T3 oHSV expressed IL-12, PD-1 Ab were restricted to the tumor bed whereas the induced IFN-γ accumulated to high levels both in tumor bed and in bl.. View More»
  DOI: 10.35248/2471-9552.19.5.154

  Abstract HTML PDF